Insider · CIK 0001263175

BYRNES ROBERT F

Reports to the SEC for 2 companies · NEWARK, CA

sec.gov

Transactions

Companies

Filings

CIK

0001263175

Forms 4 and 5

Insider transactions

23 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2020-05-14	Revance Therapeutics, Inc.A Award	Director	AAward	+6,000 sh	—	—	16,500
2020-05-14	Revance Therapeutics, Inc.Stock Option (Right to buy)A Award	Director	AAward	+12K sh	—	—	12,000
2019-05-09	Revance Therapeutics, Inc.A Award	Director	AAward	+4,500 sh	—	—	10,500
2019-05-09	Revance Therapeutics, Inc.Stock Option (Right to buy)A Award	Director	AAward	+9,000 sh	—	—	9,000
2018-05-10	Revance Therapeutics, Inc.A Award	Director	AAward	+3,000 sh	—	—	6,000
2018-05-10	Revance Therapeutics, Inc.Stock Option (Right to buy)A Award	Director	AAward	+6,000 sh	—	—	6,000
2017-05-11	Revance Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+6,000 sh	—	—	6,000
2017-05-11	Revance Therapeutics, Inc.A Award	Director	AAward	+3,000 sh	—	—	3,000
2016-05-05	Revance Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+8,000 sh	—	—	8,000
2016-02-24	Revance Therapeutics, Inc.G Gift	Director	GGift	−11K sh	—	—	0
2016-02-24	Revance Therapeutics, Inc.G Gift	Director	GGift	+11K sh	—	—	13,665
2016-02-12	Revance Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+5,333 sh	$2.55	+$13.6K	10,999
2016-02-12	Revance Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+4,000 sh	$6.60	+$26.4K	4,000
2016-02-12	Revance Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+1,666 sh	$2.55	+$4,248.3	5,666
2016-02-12	Revance Therapeutics, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−4,000 sh	—	—	0
2016-02-12	Revance Therapeutics, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−1,666 sh	—	—	0
2016-02-12	Revance Therapeutics, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−5,333 sh	—	—	0
2015-05-07	Revance Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+8,000 sh	—	—	8,000
2014-09-17	Revance Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+2,666 sh	$3.60	+$9,597.6	2,666
2014-09-17	Revance Therapeutics, Inc.G Gift	Director	GGift	−2,666 sh	—	—	0
2014-09-17	Revance Therapeutics, Inc.G Gift	Director	GGift	+2,666 sh	—	—	2,666
2014-09-17	Revance Therapeutics, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−2,666 sh	—	—	0
2004-01-02	ENDOCARE INCStock Option (Right to Buy)A Award	Director	AAward	+5,000 sh	—	—	5,000

Recent filings

Accepted (ET)
May 154
BYRNES ROBERT F0001479290-20-000066
SEC(opens sec.gov)
May 104
BYRNES ROBERT F0001479290-19-000052
SEC(opens sec.gov)
May 114
BYRNES ROBERT F0001479290-18-000076
SEC(opens sec.gov)
May 124
Revance Therapeutics, Inc.0001209191-17-032203
SEC(opens sec.gov)
May 94
Revance Therapeutics, Inc.0001209191-16-118605
SEC(opens sec.gov)
Feb 294
Revance Therapeutics, Inc.0001209191-16-103573
SEC(opens sec.gov)
Feb 174
Revance Therapeutics, Inc.0001209191-16-099587
SEC(opens sec.gov)
May 144
Revance Therapeutics, Inc.0001209191-15-043017
SEC(opens sec.gov)
Sep 194
Revance Therapeutics, Inc.0001209191-14-058905
SEC(opens sec.gov)

Companies

Address

C/O REVANCE THERAPEUTICS, INC. 7555 GATEWAY BOULEVARD

NEWARK, CA, 94560